<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Quantum Biopharma Ltd Ordinary Shares - Class B (sub Voting) — News on 6ix</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting</link>
<description>Latest news and press releases for Quantum Biopharma Ltd Ordinary Shares - Class B (sub Voting) on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 13:16:08 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting" rel="self" type="application/rss+xml" />
<item>
<title>Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/quantum-biopharma-licensee-unbuzzd-wellness-inc-appoints-richard-buzbuzian-as-ceo-to-lead-nationwide-commercialization-of-innovative-clinically-validated-hangover-remedy-and-alcohol-metabolism-accelerant</link>
<guid isPermaLink="true">https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/quantum-biopharma-licensee-unbuzzd-wellness-inc-appoints-richard-buzbuzian-as-ceo-to-lead-nationwide-commercialization-of-innovative-clinically-validated-hangover-remedy-and-alcohol-metabolism-accelerant</guid>
<pubDate>Wed, 22 Apr 2026 13:16:08 GMT</pubDate>
<description>TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FR...</description>
</item>
<item>
<title>Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/quantum-biopharma-wins-significant-court-challenge-in-usd-dollar700000000-claim-as-defendants-joint-motion-to-dismiss-lawsuit-alleging-market-manipulation-by-cibc-world-markets-and-rbc-dominion-securities-is-denied-38</link>
<guid isPermaLink="true">https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/quantum-biopharma-wins-significant-court-challenge-in-usd-dollar700000000-claim-as-defendants-joint-motion-to-dismiss-lawsuit-alleging-market-manipulation-by-cibc-world-markets-and-rbc-dominion-securities-is-denied-38</guid>
<pubDate>Thu, 02 Apr 2026 12:30:00 GMT</pubDate>
<description>TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FR...</description>
</item>
<item>
<title>Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/quantum-biopharma-submits-investigational-new-drug-ind-application-to-united-states-food-and-drug-administration-fda-for-lucid-ms-phase-two-clinical-trial-in-multiple-sclerosis</link>
<guid isPermaLink="true">https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/quantum-biopharma-submits-investigational-new-drug-ind-application-to-united-states-food-and-drug-administration-fda-for-lucid-ms-phase-two-clinical-trial-in-multiple-sclerosis</guid>
<pubDate>Wed, 01 Apr 2026 12:02:00 GMT</pubDate>
<description>TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FR...</description>
</item>
<item>
<title>Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/quantum-biopharma-signs-binding-letter-of-intent-with-allucent-to-conduct-phase-2-clinical-trial-in-multiple-sclerosis</link>
<guid isPermaLink="true">https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/quantum-biopharma-signs-binding-letter-of-intent-with-allucent-to-conduct-phase-2-clinical-trial-in-multiple-sclerosis</guid>
<pubDate>Mon, 30 Mar 2026 11:50:00 GMT</pubDate>
<description>TORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FR...</description>
</item>
<item>
<title>Quantum Biopharma's 2025 Audited Year End Financial Results Maintain 'No Going Concern' Status</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/quantum-biopharmas-2025-audited-year-end-financial-results-maintain-no-going-concern-status</link>
<guid isPermaLink="true">https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/quantum-biopharmas-2025-audited-year-end-financial-results-maintain-no-going-concern-status</guid>
<pubDate>Fri, 27 Mar 2026 12:10:00 GMT</pubDate>
<description>Multiple Sclerosis Drug Candidate Lucid-21-302 Phase 1 Trial with Toxicology Studies Complete, an...</description>
</item>
<item>
<title>Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/quantum-biopharma-announces-appointment-of-principal-investigator-for-planned-phase-2-clinical-trial-of-lucid-21-302-lucid-ms-in-multiple-sclerosis</link>
<guid isPermaLink="true">https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/quantum-biopharma-announces-appointment-of-principal-investigator-for-planned-phase-2-clinical-trial-of-lucid-21-302-lucid-ms-in-multiple-sclerosis</guid>
<pubDate>Thu, 26 Mar 2026 12:00:00 GMT</pubDate>
<description>TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FR...</description>
</item>
<item>
<title>Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/quantum-biopharma-announces-peer-reviewed-journal-publication-of-groundbreaking-clinical-trial-with-unbuzzd</link>
<guid isPermaLink="true">https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/quantum-biopharma-announces-peer-reviewed-journal-publication-of-groundbreaking-clinical-trial-with-unbuzzd</guid>
<pubDate>Mon, 23 Mar 2026 12:24:00 GMT</pubDate>
<description>TORONTO, March 23, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FR...</description>
</item>
<item>
<title>Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/quantum-biopharma-announces-closing-of-initial-tranche-of-private-placement-offering</link>
<guid isPermaLink="true">https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/quantum-biopharma-announces-closing-of-initial-tranche-of-private-placement-offering</guid>
<pubDate>Fri, 20 Mar 2026 23:35:00 GMT</pubDate>
<description>THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTIO...</description>
</item>
<item>
<title>INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-quantum-biopharma-ltd-of-class-action-lawsuit-and-upcoming-deadlines-qntm</link>
<guid isPermaLink="true">https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-quantum-biopharma-ltd-of-class-action-lawsuit-and-upcoming-deadlines-qntm</guid>
<pubDate>Fri, 20 Feb 2026 00:29:00 GMT</pubDate>
<description>INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum B...</description>
</item>
<item>
<title>Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma, Ltd. Investors</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/portnoy-law-firm-announces-class-action-on-behalf-of-quantum-biopharma-ltd-investors-1</link>
<guid isPermaLink="true">https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/portnoy-law-firm-announces-class-action-on-behalf-of-quantum-biopharma-ltd-investors-1</guid>
<pubDate>Tue, 17 Feb 2026 18:55:52 GMT</pubDate>
<description>LOS ANGELES, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Quantum Biopharma, ...</description>
</item>
<item>
<title>Portnoy Law Firm Announces Class Action on Behalf of Quantum Corporation Investors</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/portnoy-law-firm-announces-class-action-on-behalf-of-quantum-corporation-investors</link>
<guid isPermaLink="true">https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/portnoy-law-firm-announces-class-action-on-behalf-of-quantum-corporation-investors</guid>
<pubDate>Tue, 17 Feb 2026 14:41:57 GMT</pubDate>
<description>LOS ANGELES, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Quantum Biopharma L...</description>
</item>
<item>
<title>Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/bronstein-gewirtz-and-grossman-llc-urges-quantum-biopharma-ltd-investors-to-act-class-action-filed-alleging-investor-harm</link>
<guid isPermaLink="true">https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/bronstein-gewirtz-and-grossman-llc-urges-quantum-biopharma-ltd-investors-to-act-class-action-filed-alleging-investor-harm</guid>
<pubDate>Thu, 05 Feb 2026 18:57:29 GMT</pubDate>
<description>NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz &amp; Grossman, LLC, a nationally ...</description>
</item>
<item>
<title>CONTACT:&#xA0;INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/contactandxa0investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-quantum-biopharma-ltd-of-class-action-lawsuit-and-upcoming-deadlines-qntm</link>
<guid isPermaLink="true">https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/contactandxa0investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-quantum-biopharma-ltd-of-class-action-lawsuit-and-upcoming-deadlines-qntm</guid>
<pubDate>Tue, 03 Feb 2026 18:12:19 GMT</pubDate>
<description>NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit h...</description>
</item>
<item>
<title>Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma Ltd. Investors</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/portnoy-law-firm-announces-class-action-on-behalf-of-quantum-biopharma-ltd-investors</link>
<guid isPermaLink="true">https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/portnoy-law-firm-announces-class-action-on-behalf-of-quantum-biopharma-ltd-investors</guid>
<pubDate>Mon, 02 Feb 2026 15:46:08 GMT</pubDate>
<description>LOS ANGELES, Feb. 02, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Quantum Biopharma L...</description>
</item>
<item>
<title>CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/contact-investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-quantum-biopharma-ltd-of-class-action-lawsuit-and-upcoming-deadlines-qntm</link>
<guid isPermaLink="true">https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/contact-investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-quantum-biopharma-ltd-of-class-action-lawsuit-and-upcoming-deadlines-qntm</guid>
<pubDate>Thu, 29 Jan 2026 15:00:00 GMT</pubDate>
<description>CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ...</description>
</item>
<item>
<title>QNTM DEADLINE ALERT: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Quantum Biopharma Ltd. (QNTM) and Lead Plaintiff Deadline on February 23, 2026</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/qntm-deadline-alert-kaplan-fox-reminds-investors-of-a-class-action-lawsuit-against-quantum-biopharma-ltd-qntm-and-lead-plaintiff-deadline-on-february-23-2026</link>
<guid isPermaLink="true">https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/qntm-deadline-alert-kaplan-fox-reminds-investors-of-a-class-action-lawsuit-against-quantum-biopharma-ltd-qntm-and-lead-plaintiff-deadline-on-february-23-2026</guid>
<pubDate>Mon, 12 Jan 2026 15:03:28 GMT</pubDate>
<description>NEW YORK, NY - January 12, 2026 ( NEWMEDIAWIRE ) -&#xA0; Kaplan Fox &amp; Kilsheimer LLP announc...</description>
</item>
<item>
<title>QUANTUM BIOPHARMA DEADLINE FOR LEADERSHIP is February 23, 2026 in a Securities Fraud Lawsuit - Contact Kaplan Fox & Kilsheimer LLP</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/quantum-biopharma-deadline-for-leadership-is-february-23-2026-in-a-securities-fraud-lawsuit-contact-kaplan-fox-and-kilsheimer-llp</link>
<guid isPermaLink="true">https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/quantum-biopharma-deadline-for-leadership-is-february-23-2026-in-a-securities-fraud-lawsuit-contact-kaplan-fox-and-kilsheimer-llp</guid>
<pubDate>Sat, 10 Jan 2026 12:03:14 GMT</pubDate>
<description>NEW YORK, NY - January 10, 2026 ( NEWMEDIAWIRE ) -&#xA0; Kaplan Fox &amp; Kilsheimer LLP announc...</description>
</item>
<item>
<title>Deadline to Lead in Securities Class Action Against Quantum Biopharma Ltd. (QNTM) is February 23, 2026 - Contact Kaplan Fox</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/deadline-to-lead-in-securities-class-action-against-quantum-biopharma-ltd-qntm-is-february-23-2026-contact-kaplan-fox</link>
<guid isPermaLink="true">https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/deadline-to-lead-in-securities-class-action-against-quantum-biopharma-ltd-qntm-is-february-23-2026-contact-kaplan-fox</guid>
<pubDate>Fri, 09 Jan 2026 18:03:03 GMT</pubDate>
<description>NEW YORK, NY - January 9, 2026 ( NEWMEDIAWIRE ) -&#xA0; Kaplan Fox &amp; Kilsheimer LLP announce...</description>
</item>
<item>
<title>QNTM CLASS ACTION DEADLINE: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Quantum Biopharma Ltd. (QNTM) and Lead Plaintiff Deadline on February 23, 2026</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/qntm-class-action-deadline-kaplan-fox-reminds-investors-of-a-class-action-lawsuit-against-quantum-biopharma-ltd-qntm-and-lead-plaintiff-deadline-on-february-23-2026</link>
<guid isPermaLink="true">https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/qntm-class-action-deadline-kaplan-fox-reminds-investors-of-a-class-action-lawsuit-against-quantum-biopharma-ltd-qntm-and-lead-plaintiff-deadline-on-february-23-2026</guid>
<pubDate>Thu, 08 Jan 2026 16:04:11 GMT</pubDate>
<description>NEW YORK, NY - January 8, 2026 ( NEWMEDIAWIRE ) -&#xA0; Kaplan Fox &amp; Kilsheimer LLP announce...</description>
</item>
<item>
<title>QNTM DEADLINE: Investors of Quantum Biopharma Ltd. (QNTM) are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on February 23, 2026</title>
<link>https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/qntm-deadline-investors-of-quantum-biopharma-ltd-qntm-are-encouraged-to-contact-kaplan-fox-before-the-lead-plaintiff-deadline-on-february-23-2026</link>
<guid isPermaLink="true">https://6ix.com/company/quantum-biopharma-ltd-ordinary-shares-class-b-sub-voting/news/qntm-deadline-investors-of-quantum-biopharma-ltd-qntm-are-encouraged-to-contact-kaplan-fox-before-the-lead-plaintiff-deadline-on-february-23-2026</guid>
<pubDate>Wed, 07 Jan 2026 14:03:03 GMT</pubDate>
<description>NEW YORK, NY - January 7, 2026 ( NEWMEDIAWIRE ) -&#xA0; Kaplan Fox &amp; Kilsheimer LLP announce...</description>
</item>
</channel>
</rss>